Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accumulated Expenses: 2010-2017

Historic Accumulated Expenses for Vanda Pharmaceuticals (VNDA) over the last 8 years, with Dec 2017 value amounting to $5.3 million.

  • Vanda Pharmaceuticals' Accumulated Expenses fell 85.47% to $4.4 million in Q1 2018 from the same period last year, while for Mar 2018 it was $4.4 million, marking a year-over-year decrease of 85.47%. This contributed to the annual value of $5.3 million for FY2017, which is 84.40% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Accumulated Expenses of $5.3 million as of FY2017, which was down 84.40% from $34.1 million recorded in FY2016.
  • In the past 5 years, Vanda Pharmaceuticals' Accumulated Expenses registered a high of $35.5 million during FY2015, and its lowest value of $602,000 during FY2014.
  • Over the past 3 years, Vanda Pharmaceuticals' median Accumulated Expenses value was $34.1 million (recorded in 2016), while the average stood at $25.0 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Accumulated Expenses slumped by 88.38% in 2014, and later skyrocketed by 5,805.32% in 2015.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Accumulated Expenses stood at $5.2 million in 2013, then plummeted by 88.38% to $602,000 in 2014, then soared by 5,805.32% to $35.5 million in 2015, then dropped by 4.01% to $34.1 million in 2016, then crashed by 84.40% to $5.3 million in 2017.